Introduction
1,25-dihydroxyvitamin D 3 (1,25D), a well known anti-rachitic agent [1] , also has antitumor and pro-differentiating activities towards cancer cells [2, 3] . This is why many 1,25D analogues with improved anti-proliferative and pro-differentiating activities, as well as lower calcemic effects have been designed [4, 5] . Mechanistic studies of 1,25D analogues provide important information that allow us to determine which structural modifications of the 1,25D molecule are responsible for their changed biological properties. 1,25D exerts most of its biological functions via the vitamin D receptor (VDR) [6] . Many of VDR target genes are connected with the calcium/phosphate homeostasis, but also with anti-proliferative and pro-differentiating actions of 1,25D in noncalcemic tissues. CYP24A1, the gene most strongly regulated by VDR, encodes an enzyme responsible for degradation of 1,25D [7] . Another primary VDR-target gene is CD14, a monocytic cell differentiation marker, and a co-receptor for bacterial lipopolysaccharide, characteristic for monocytes and macrophages [8, 9] .
It has been long believed in the field that only subtle changes to the structure of vitamin D might result in beneficial changes in the activity profile. Therefore, all the vitamin D drug substances were modified in a single point of the molecule. This is why in our search for vitamin D analogues of selective activity profile we modified up to now the molecule exclusively in the aliphatic side-chain. The most active analogues we obtained contained one-carbon unit extended (24a-homo) and rigidified (conjugated diene) side-chain (PRI-1906), additionally homologated at both terminal carbons (PRI-1907).
In our attempt to lower the toxicity of our PRI-1907 and to increase its biological activity we have now synthesised new generation of analogues of 1,25-dihydroxyvitamin D 2 modified in two distinct parts of molecule. In these structures we have combined our optimised side-chain of PRI-1906 and PRI-1907 [10-12] with the known 19-nor modification. This modification was previously introduced in the structure of a drug substance (paricalcitol, PRI-5100) and its 24-epi analogue (PRI-5101) [13] , and we use them as a reference in our experiments. In this paper we present our in vivo and in vitro evaluation of the resulting analogues PRI-5201 and PRI-5202 compared to the previously obtained ones and to 1,25D. The structures of the analogues are presented in Fig. 1 .
Materials and methods

Chemicals and antibodies
1,25D and analogues were synthesised at the Pharmaceutical Research Institute (Warsaw, Poland). Antibodies for flow cytometry were from ImmunoTools (Friesoythe, Germany). Antibodies for western blots and chemiluminescence blotting substrate were from Santa Cruz (Santa Cruz, CA).
Cell lines, flow cytometry and western blots
HL60 cells (Institute of Immunology and Experimental Therapy in Wroclaw, Poland) and HaCat cells (Dr. Miguel Quintanilla, Instituto de Investigaciones Biomedicas Alberto Sols, Madrid, Spain) were cultured using standard conditions. HL60 cells were incubated, labeled and analysed by flow cytometry as we have described before [10] . Western blotting was performed using nuclear fractions from cells as previously described [10] .
cDNA synthesis and real time PCR
Total RNA was isolated and transcribed into cDNA. Then Real time PCR reaction was performed as previously described [10] .
Human VDR binding assay
Binding affinity to VDR was evaluated using a PolarScreen 
Calcemic activity in vivo
All animals studies were approved by the University of Santiago de Compostela Ethics Committee for Animal Experiments. Male CD-1 mice (age matched, between 6 and 8 weeks) were obtained from Charles River Laboratories (L'Arbresle, France). The compounds were resuspended in sesame oil and administered intraperitoneally (0.3 mg/kg) every other day for 21 days. Ethanol resuspended in sesame oil was used as the control for this experiment. Serum calcium levels were measured a day after the last dose using the QuantiChom Calcium Assay Kit (BioAssay Systems, Hayward, CA, USA) following manufacturer's guidelines. The weight of mice was measured every week.
Statistical analysis
All experiments were repeated at least three times. Values are expressed as means AE SD. Dose response curves for cell differentiation and competitive VDR binding, calculation of EC 50 and IC 50 values, as well as analysis of statistical significance (ANOVA followed by t-tests) were performed using GraphPad Prism 6 software (San Diego, CA, USA).
Results
Calcemic activities in vivo
First, we tested calcemic activities of our compounds in mice. The calcium serum levels induced by 1,25D and by all analogues, compared to the vehicle (ethanol) treated mice, are presented in Fig. 2A . Since toxic effects are not always directly connected to calcemia induced by 1,25D or by the analogues, we also examined the extent to which administration of the compounds affected the body weight of mice. The changes in body weight are related to overall toxicity (Fig. 2B) . The results show that all of the tested analogues are less calcemic than 1,25D. The analogues PRI-1907, and to lower extent PRI-5202, exerted some general toxicity, similarly to 1,25D, as they affected weight gain of the mice. It is noteworthy, that mice receiving analogue PRI-5201, showed no significant change in body weight when compared to vehicletreated mice.
Binding of analogues to VDR
Since VDR is the primary target for 1,25D and analogues in cells, it is important to study the affinities of given analogues to this protein [14] . The experiments were performed using a fluorescence polarisation (FP)-based competition assay. The binding of analogues to VDR was tested over a wide range of concentrations and was compared to binding of 1,25D to the receptor. Doseresponse curves were plotted (data not shown), and IC 50 values were calculated from these dose-response curves (Table 1) .
Differentiation of HL60 cells
HL60 cells were used to determine how the subtle changes introduced to the structure of analogues influenced their prodifferentiating activities [15, 16] . The cells were exposed to compounds at a wide concentration range for 96 h and then the expression of monocyte/macrophage differentiation markers CD11b and CD14 was studied using flow cytometry. Since treated cells expressed CD14 at a greater extent than CD11b, we therefore present the data obtained for this differentiation marker. Doseresponse curves allowed us to calculate EC 50 value for each analogue ( Table 1 ). This data confirmed our earlier findings that analogue PRI-1907 is about one order of magnitude more active than 1,25D [10, 12] , and it also shows that the new analogues, PRI-5201 and PRI-5202 are even more active in inducing AML cell differentiation than PRI-1907. A. Calcium levels in mice treated with the natural hormone 1,25D and compounds. Five mice per group were treated with 0.3 mg/kg of analogues, 1,25D or control every other day during 3 weeks, and calcium levels were measured on day 21. Error bars represent the standard deviation (SD). Analogues were compared to 1,25D, ****P 0.0001. B. Effect of analogues on body weight of mice. Mice were weighed every other day for 3 weeks. Analogues were compared to either the control (#) or to 1,25D (*) *P 0.05, **P 0.01, ###P 0.001, ####P 0.0001, ns P > 0.05. 
Transcription-inducing activities of 1,25D and analogues
1,25D and its analogues are ligands of VDR, a receptor which is a ligand-activated transcription factor. The activity of analogues can be measured by the levels of transcription which they induce. In order to compare the transcriptional activities of the analogues we tested the expression of CYP24A1 and CD14 genes in HL60 cells exposed for 48 h (CD14) and 96 h (CYP24A1) to the analogues at 1 nM and 10 nM (not shown) concentrations. The results of CYP24A1 expression are presented in Fig. 3A , and CD14 expression in Fig. 3B . Again, the analogues PRI-1907, PRI-5201 and PRI-5202 are more active than 1,25D, especially at 1 nM concentrations.
Nuclear translocation and accumulation of VDR in response to analogues
The ligand-induced translocation of VDR into the nucleus is a critical step required for transcriptional activity of VDR [17] . Given that VDR nuclear accumulation and pro-differentiating activity were correlated for previously tested analogues, we therefore studied how new analogues influence the levels of VDR protein in HL60 cells. We analysed VDR levels in nuclear fractions of cells exposed for different times to analogues at 1 nM concentration. Actin was used as a control, as it is a protein that does not change during HL60 cell differentiation. A significant increase in the level of VDR in the nucleus was seen as early as 3 h after exposing the cells to analogues, but at this time-point the VDR level does not correlate with differentiation-inducing activity of the given analogue. At later time-points, from 24 h (not shown) to 72 h post treatment, the amount of VDR in the nucleus correlates with the differentiation effect (Fig. 4) .
Activation of C/EBPb by 1,25D and analogues
In addition, we have examined the ability of tested analogues to increase expression of C/EBPb protein. Our previous studies provided strong experimental evidence that 1,25D up-regulates expression of this protein in HL60 cells [18] and, it has been shown that down-regulation of C/EBPb protein levels, using antisense technology, attenuates 1,25D-induced differentiation in this cell line [19, 20] . C/EBPb expression in response to 1,25D treatment is undetectable at 24 h but it rises gradually to reach maximal levels at 3-4 days of treatment [18] . Therefore, we determined C/EBPb protein levels in nuclear fractions of HL60 cells treated for 72 h with 1 nM 1,25D and analogues. The results are presented as Fig. 3 . Impact of 1,25D and analogues on mRNA levels. A. HL60 cells were exposed to 1 nM 1,25D and analogues for 96 h and then the expression of CYP24A1 mRNA was tested in Real Time PCR. The graph shows mean values (AESEM) of fold changes in CYP24A1 mRNA levels relative to GAPDH. B. HL60 cells were exposed to 1 nM 1,25D and analogues for 48 h and then the expression of CD14 mRNA was tested in Real Time PCR. The graph shows mean values (AESEM) of fold changes in CD14 mRNA levels relative to GAPDH. Fig. 4 . Nuclear localisation of VDR protein in HL60 exposed to 1,25D or analogues. HL60 cells were exposed to 1,25D or analogues at 1 nM concentration for 3 h and 72 h and then expression of VDR was determined in the nuclear fractions.
western blots in Fig. 5 which show that increased nuclear expression of C/EBPb2 and C/EBPb3 correlates well with the final cell differentiation effect.
Pro-differentiating activity of analogues towards human keratinocytes
In order to determine whether the increased potency of analogues was limited to AML cells, we tested the differentiation effects of analogues towards human keratinocyte cell line HaCat [21] . After exposure to 1,25D and to other VDR ligands these cells change their growth properties and phenotype. This experiment showed in a qualitative manner the ability of analogues to induce differentiation of keratinocytes. The results presented in Fig. 6 show that all the analogues induced phenotype changes to the HaCat cells which are characteristic for differentiated cells.
Discussion
1,25D is a very active compound with many biological activities, including induction of cell differentiation, immunomodulation and inhibition of cell proliferation [2, 3, 22] . 1,25D is also a potent regulator of calcium/phosphate metabolism, so when used at pharmacological concentrations, it can induce hypercalcemia [1] . To utilise the therapeutic properties of 1,25D, it is necessary to obtain analogues that would have increased benefits to risk ratio, as compared to 1,25D [5] . The analogues should be selective and should have increased pro-differentiating and anti-proliferative, and lowered calcemic activities. Regulation of the effective concentration and biological activity of 1,25D is maintained at multiple levels including transport of the analogue to the cell, intracellular localisation of the receptor, effective activation of transcription and degradation of 1,25D to inactive metabolites [23] . Therefore, it is necessary to complete a wide range of experiments to fully characterise new vitamin D analogues.
Our experiments revealed that the new, double-point modified analogues do not increase serum calcium levels as much as 1,25D. Their toxic effects, displayed as their ability to influence mice body weight, are lower than that of 1,25D, and also lower than toxicity induced by PRI-1907, the most active compound out of the singlepoint modified vitamin D 2 analogues. The pro-differentiating activities of PRI-5201 and PRI-5202 are more than an order of magnitude higher than that of 1,25D which suggests that they can be applied at lower concentrations to obtain anti-cancer or immunomodulatory effects. New, toxicological screening of these analogues, in a broader range of concentrations should reveal whether they are suitable for long-term therapy.
In our previous experiments, we have shown that the high differentiation-inducing potential of PRI-1907 correlated with its ability to increase the expression of the master regulator of monocyte differentiation, namely the C/EBPb transcription factor and with upregulation of VDR target CD14 gene. The same correlation was observed for double-point modified analogues (PRI-5201 and PRI-5202). The high pro-differentiating activities of PRI-5201 and PRI-5202, as compared to PRI-5100 and PRI-5101, cannot be explained by the binding affinities of these analogues for VDR. The affinity of PRI-5100 and PRI-5101 is more than four times higher than that of 1,25D. Interestingly, the affinity of PRI-5101, with the unnatural configuration at C-24 in the side-chain, is higher than that of PRI-5100 with the natural side-chain of 1,25-dihydroxyvitamin D 2 . The affinity of the new analogue PRI-5201 is two times lower than that of PRI-5100 and the affinity of PRI-5202 is about seven times lower than that of PRI-5100 and PRI-5101. Therefore, we suggest that an interplay of different signal transduction pathways, genomic and non-genomic events, and the ability of given analogue to stabilise VDR in the cell nucleus of target cells (see Fig. 4 ) are all important to eventual biological activity. The combination of selected structural fragments (sidechain of analogue PRI-1907 and 19-nor modification) has been shown to be very beneficial to the activity profile of vitamin D analogues. Until now analogues PRI-5201 and PRI-5202 represent the most active vitamin D compounds we designed, synthesised and biologically evaluated. Further modifications of the vitamin D structure leading to the same direction as to biological activity are under way in our laboratories.
